# DC-CIK Combined With TACE in the Treatment of Hepatocellular Carcinoma

> **NCT02487017** · PHASE2 · UNKNOWN · sponsor: **Shenzhen Hornetcorn Bio-technology Company, LTD** · enrollment: 60 (estimated)

## Conditions studied

- Hepatocellular Carcinoma
- Neoplasms
- Digestive System Neoplasms

## Interventions

- **PROCEDURE:** Transcatheter Arterial Chemoembolization (TACE)
- **BIOLOGICAL:** DC-CIK

## Key facts

- **NCT ID:** NCT02487017
- **Lead sponsor:** Shenzhen Hornetcorn Bio-technology Company, LTD
- **Sponsor class:** INDUSTRY
- **Phase:** PHASE2
- **Study type:** INTERVENTIONAL
- **Status:** UNKNOWN
- **Start date:** 2015-05
- **Primary completion:** 2018-12
- **Final completion:** 2018-12
- **Target enrollment:** 60 (ESTIMATED)
- **Last updated:** 2016-05-24

## Collaborators

- [object Object]

## Primary source

ClinicalTrials.gov registry: https://clinicaltrials.gov/study/NCT02487017

## Citation

> US National Library of Medicine, ClinicalTrials.gov registration NCT02487017, "DC-CIK Combined With TACE in the Treatment of Hepatocellular Carcinoma". Retrieved via AI Analytics 2026-05-28 from https://api.ai-analytics.org/clinical/NCT02487017. Licensed CC0.

---

*[Clinical trials dataset](/datasets/clinical-trials) · CC0 1.0*